Dihexa (5mg x 60 Capsules = 300mg)

Source: PubChem

Amino Acid Sequence: Hexanoyl-Tyr-Ile-Unk (N-Hexanoyl-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide)
Molecular Formula: C₂₇H₄₄N₄O₅
Molecular Weight: 504.7 g/mol
PubChem CID: 129010512
CAS Number: 1401708-83-5
Reported Synonyms: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, PNB-0408, fosgonimeto

Dihexa is an N-terminally acylated peptide analogue structurally derived from angiotensin IV. Structural descriptions in the literature note the presence of an N-hexanoyl modification, which has been referenced in discussions of peptide physicochemical properties in experimental contexts.

All biochemical descriptions are limited to compositional and structural attributes reported in non-clinical research sources.

In the scientific literature, Dihexa has been referenced in non-clinical research settings involving cellular assays, ex-vivo preparations, and animal model studies. These references describe experimental contexts in which molecular interactions, signaling components, and pathway-associated markers were observed and recorded.

Research contexts reported include examination of:

• HGF/c-Met receptor-associated signaling components
• Angiotensin IV (AT4)-related molecular interactions
• Insulin-regulated aminopeptidase (IRAP)-associated biology
• Intracellular signaling cascade components
• Extracellular matrix–associated molecular markers

All reported applications remain confined to descriptive investigation within controlled laboratory research environments.

Mechanistic discussions in preclinical publications describe Dihexa in relation to the hepatocyte growth factor (HGF) / c-Met receptor system, a receptor tyrosine kinase complex associated with intracellular signaling cascades such as PI3K/AKT and MAPK-related pathways.

Additional references discuss angiotensin IV–associated signaling alongside insulin-regulated aminopeptidase (IRAP), a transmembrane aminopeptidase reported in studies of peptide processing, endosomal trafficking, and compartmentalized signaling.

These pathway descriptions are limited to molecular and biochemical observations reported in experimental research settings and do not imply functional outcomes.

Preclinical studies referenced in the scientific literature describe observations involving Dihexa and related angiotensin IV analogues in cellular and non-clinical animal models. Reported observations include measurement of signaling-associated proteins, pathway-linked molecular markers, and morphology-related features documented under defined experimental conditions.

Separate rodent studies have reported experimental observations involving Dihexa within study-specific protocols, including histological and biochemical assessments. All reported findings are restricted to the experimental systems employed and do not extend beyond laboratory research contexts.

Dihexa is supplied as a research-grade peptide material. Identity and composition have been reported as verified using analytical techniques commonly applied to RUO materials, including high-performance liquid chromatography (HPLC) and mass spectrometry (MS).

Handling, storage, and analytical verification parameters are determined by individual laboratories in accordance with internal research protocols.